Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

NCT06774963 is registered in ClinicalTrials.gov with NextCure, Inc. as lead sponsor.

NCT NCT06774963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06774963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors
Lead sponsor
NextCure, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
January 7, 2025
Completion date
December 31, 2026
Enrollment
145 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors, biliary tract cancer, breast cancer, endometrial cancer, non-small cell lung cancer, ovarian cancer